By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc. (LVZPF)

OTC Market Data in USD, Fundamentals in CNY
$3.43
$0.00
0.00%
Last Update: 2 Sept 2025, 00:00
$3.98B
Market Cap
13.10
P/E Ratio (TTM)
4.45%
Forward Dividend Yield
$3.20 - $3.63
52 Week Range

LVZPF Stock Price Chart

Explore Livzon Pharmaceutical Group Inc. interactive price chart. Choose custom timeframes to analyze LVZPF price movements and trends.

LVZPF Company Profile

Discover essential business fundamentals and corporate details for Livzon Pharmaceutical Group Inc. (LVZPF) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

29 Jun 2018

Employees

9.07K

CEO

Yanggang Tang

Description

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.

LVZPF Financial Timeline

Browse a chronological timeline of Livzon Pharmaceutical Group Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 21 Apr 2026

Upcoming earnings on 21 Oct 2025

Earnings released on 20 Aug 2025

EPS came in at $0.10 surpassing the estimated $0.08 by +21.06%, while revenue for the quarter reached $431.40M , beating expectations by +9.61%.

Dividend declared on 13 Jun 2025

A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 11 Jul 2025.

Earnings released on 21 Apr 2025

EPS came in at $0.10 surpassing the estimated $0.10 by +1.12%, while revenue for the quarter reached $436.82M , beating expectations by +1.65%.

Earnings released on 31 Dec 2024

EPS came in at $0.06 , while revenue for the quarter reached $374.00M .

Earnings released on 23 Oct 2024

EPS came in at $0.08 falling short of the estimated $0.08 by -4.05%, while revenue for the quarter reached $399.31M , beating expectations by +2.47%.

Earnings released on 22 Aug 2024

EPS came in at $0.08 surpassing the estimated $0.08 by +10.82%, while revenue for the quarter reached $413.01M , missing expectations by -6.39%.

Dividend declared on 8 Jul 2024

A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 5 Aug 2024.

Earnings released on 23 Apr 2024

EPS came in at $0.09 surpassing the estimated $0.08 by +11.28%, while revenue for the quarter reached $448.35M , missing expectations by -3.51%.

Earnings released on 12 Jan 2024

EPS came in at $0.05 , while revenue for the quarter reached $386.67M .

Earnings released on 30 Sept 2023

EPS came in at $0.07 falling short of the estimated $0.08 by -17.84%, while revenue for the quarter reached $405.83M , missing expectations by -14.99%.

Dividend declared on 4 Jul 2023

A dividend of $0.22 per share was announced, adjusted to $0.22. The dividend was paid on 31 Jul 2023.

Earnings released on 30 Jun 2023

EPS came in at $0.08 falling short of the estimated $0.08 by -2.72%, while revenue for the quarter reached $452.29M , missing expectations by -7.18%.

Earnings released on 30 Mar 2023

EPS came in at $0.06 surpassing the estimated $0.06 by +7.51%, while revenue for the quarter reached $496.37M , missing expectations by -9.57%.

Earnings released on 31 Dec 2022

EPS came in at $0.06 , while revenue for the quarter reached $458.81M .

Earnings released on 25 Oct 2022

EPS came in at $0.07 surpassing the estimated $0.07 by +1.96%, while revenue for the quarter reached $445.90M , missing expectations by -7.07%.

Earnings released on 9 Aug 2022

EPS came in at $0.07 falling short of the estimated $0.09 by -16.67%, while revenue for the quarter reached $421.29M , missing expectations by -14.57%.

Dividend declared on 31 May 2022

A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 24 Jun 2022.

Earnings released on 21 Apr 2022

EPS came in at $0.09 falling short of the estimated $0.10 by -10.59%, while revenue for the quarter reached $547.55M , beating expectations by +4.23%.

Earnings released on 31 Dec 2021

EPS came in at $0.05 , while revenue for the quarter reached $423.12M .

Earnings released on 25 Oct 2021

EPS came in at $0.06 falling short of the estimated $0.10 by -38.81%, while revenue for the quarter reached $485.55M .

Earnings released on 24 Aug 2021

EPS came in at $0.09 matching the estimated $0.09, while revenue for the quarter reached $446.21M .

Dividend declared on 1 Jun 2021

A dividend of $0.19 per share was announced, adjusted to $0.19. The dividend was paid on 25 Jun 2021.

Earnings released on 21 Apr 2021

EPS came in at $0.08 falling short of the estimated $0.10 by -15.39%, while revenue for the quarter reached $510.22M .

Earnings released on 31 Dec 2020

EPS came in at $0.05 , while revenue for the quarter reached $397.51M .

Earnings released on 23 Oct 2020

EPS came in at $0.07 surpassing the estimated $0.06 by +7.32%, while revenue for the quarter reached $416.45M .

LVZPF Stock Performance

Access detailed LVZPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run